Gerry Dolan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gerry Dolan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Brenda Riske
Mountain States Regional Hemophilia and Thrombosis Center
1 shared publicationC. Grimley
Department of Haematology, Nottingham University Hospitals NHS Trust, Queens Medical Centre Campus, Nottingham, UK
1 shared publicationC. Hermans
Saint‐Luc University Hospital, Catholic University of Louvain, Brussels, Belgium
1 shared publicationCaesar Guerrero
Los Angeles Orthopaedic Hospital
1 shared publicationCarmen Altisent
Hospital Vall d’Hebron
1 shared publicationCedric Hermans
Saint-Luc University Hospital
1 shared publication
Latest Publications
- 16 March 2012
- Published by Springer Nature in Advances in Therapy
- Vol. 29 (1) , 1-16
Advances in Hemophilia Care: Report of Two Symposia at the Hemophilia 2010 World Congress
The World Federation of Hemophilia (WFH) 2010 World Congress held in Buenos Aires, Argentina, in July 2010, attracted more than 4,300 participants from 106 countries. This report summarizes two symposia held during the congress. The first, titled “Emerging Co-Morbidities in the Aging Hemophilia Population: Healthcare Challenges and Treatment Opportunities,” chaired by Gerry Dolan, MD, and Jussara Almeida Cruz, MD, examined the co-morbidities experienced by the aging hemophilic patient population, such as cardiovascular disease, cancer, arthritis, osteoporosis, hypertension, and obesity. In addition, Bayer’s products in preclinical and clinical development were reviewed, including a novel factor VIIa variant and a long-acting factor VIII molecule, i.e., one that has undergone site-specific PEGylation (attachment of polyethylene glycol [PEG] polymer chains to another molecule). The other symposium, titled “Practical Steps to Making Better Care for Hemophilia Patients a Reality,” chaired by Carmen Altisent, MD, and Cesar Guerrero, RN, reviewed the steps that hemophilia caregivers can take to improve the care of their patients. Issues such as the treatment of hemarthroses, the role of the research nurse, and the management of pediatric patients transitioning to adulthood were discussed.
- 16 March 2012
- Published by Springer Nature in Advances in Therapy
- Vol. 29 (1) , 1-16
Advances in Hemophilia Care: Report of Two Symposia at the Hemophilia 2010 World Congress
The World Federation of Hemophilia (WFH) 2010 World Congress held in Buenos Aires, Argentina, in July 2010, attracted more than 4,300 participants from 106 countries. This report summarizes two symposia held during the congress. The first, titled “Emerging Co-Morbidities in the Aging Hemophilia Population: Healthcare Challenges and Treatment Opportunities,” chaired by Gerry Dolan, MD, and Jussara Almeida Cruz, MD, examined the co-morbidities experienced by the aging hemophilic patient population, such as cardiovascular disease, cancer, arthritis, osteoporosis, hypertension, and obesity. In addition, Bayer’s products in preclinical and clinical development were reviewed, including a novel factor VIIa variant and a long-acting factor VIII molecule, i.e., one that has undergone site-specific PEGylation (attachment of polyethylene glycol [PEG] polymer chains to another molecule). The other symposium, titled “Practical Steps to Making Better Care for Hemophilia Patients a Reality,” chaired by Carmen Altisent, MD, and Cesar Guerrero, RN, reviewed the steps that hemophilia caregivers can take to improve the care of their patients. Issues such as the treatment of hemarthroses, the role of the research nurse, and the management of pediatric patients transitioning to adulthood were discussed.
- 22 June 2010
- Published by Wiley in Haemophilia
- Vol. 16 (s5) , 11-16
The challenge of an ageing haemophilic population
Summary. Life expectancy for haemophilia has increased significantly in many countries. This represents a major success of the improved safety of therapeutic materials to treat haemophilia and of improved quality of care. This improved longevity will generate a population of older individuals with haemophilia with complex medical problems associated with age and managing such clinical issues is likely to be challenging.
- 22 June 2010
- Published by Wiley in Haemophilia
- Vol. 16 (s5) , 11-16
The challenge of an ageing haemophilic population
Summary. Life expectancy for haemophilia has increased significantly in many countries. This represents a major success of the improved safety of therapeutic materials to treat haemophilia and of improved quality of care. This improved longevity will generate a population of older individuals with haemophilia with complex medical problems associated with age and managing such clinical issues is likely to be challenging.
- 1 January 2009
- Published by Wiley in Haemophilia
- Vol. 15, 20-27
Challenges and controversies in haemophilia care in adulthood
Overall life expectancy and quality of life among persons with haemophilia have increased in recent years, primarily because of the advances in factor replacement therapy and better treatment of infectious diseases. Older haemophilic patients now face aging co-morbidities that are common in the general male population, such as cardiovascular or metabolic diseases, prostate hypertrophy and hepatic, prostate and other cancers. The prevalence of cardiovascular disease and incidence of vascular events among older haemophilic patients can be expected to increase and haemophilic patients may become prone to some cardiovascular risk factors, warranting preventative measures. The treatment of long-term complications of hepatitis C virus infection such as liver cirrhosis and hepatic cancer can be expected to be required in a large portion of the older haemophilia population for some years to come. Appropriate antiviral treatment and close monitoring for possible disease advancement will constitute an important part of routine medical care, and special considerations may be appropriate in conjunction with invasive procedures, chemo- or radiotherapy. At the moment, hard data on which to base the management of these conditions are largely lacking, but can be expected to increase dramatically in the coming decades. In the meantime, the ageing population of haemophilia patients should be offered the same comprehensive health care offered to the general population, which may require a restructuring of health care delivery.
- 1 January 2009
- Published by Wiley in Haemophilia
- Vol. 15, 20-27
Challenges and controversies in haemophilia care in adulthood
Overall life expectancy and quality of life among persons with haemophilia have increased in recent years, primarily because of the advances in factor replacement therapy and better treatment of infectious diseases. Older haemophilic patients now face aging co-morbidities that are common in the general male population, such as cardiovascular or metabolic diseases, prostate hypertrophy and hepatic, prostate and other cancers. The prevalence of cardiovascular disease and incidence of vascular events among older haemophilic patients can be expected to increase and haemophilic patients may become prone to some cardiovascular risk factors, warranting preventative measures. The treatment of long-term complications of hepatitis C virus infection such as liver cirrhosis and hepatic cancer can be expected to be required in a large portion of the older haemophilia population for some years to come. Appropriate antiviral treatment and close monitoring for possible disease advancement will constitute an important part of routine medical care, and special considerations may be appropriate in conjunction with invasive procedures, chemo- or radiotherapy. At the moment, hard data on which to base the management of these conditions are largely lacking, but can be expected to increase dramatically in the coming decades. In the meantime, the ageing population of haemophilia patients should be offered the same comprehensive health care offered to the general population, which may require a restructuring of health care delivery.
- 8 April 2008
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 24 (5) , 1459-1472
Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature
Objectives: To investigate the relationship between time spent in the recommended target International Normalised Ratio (INR) range and the setting and intensity of anticoagulant monitoring, in both treatment-experienced and treatment-naïve atrial fibrillation (AF) patients receiving oral anticoagulation (OAC) therapy for the prevention of ischaemic stroke.Research design and methods: Systematic review of published studies on participants with atrial fibrillation on anticoagulation therapy. We compared frequent monitoring (well-controlled, according to a strict protocol) versus infrequent monitoring (frequency representative of routine clinical practice), specialised care versus usual care, and naïve versus prior anticoagulant use. Meta-analysis was performed using a random effects model.Results: 36 studies were included, 22 (primary data) of AF patients managed in line with the consensus guidelines target INR range of 2.0–3.0, and 14 studies (secondary data) of mixed patient groups, including AF...
- 8 April 2008
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 24 (5) , 1459-1472
Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature
Objectives: To investigate the relationship between time spent in the recommended target International Normalised Ratio (INR) range and the setting and intensity of anticoagulant monitoring, in both treatment-experienced and treatment-naïve atrial fibrillation (AF) patients receiving oral anticoagulation (OAC) therapy for the prevention of ischaemic stroke.Research design and methods: Systematic review of published studies on participants with atrial fibrillation on anticoagulation therapy. We compared frequent monitoring (well-controlled, according to a strict protocol) versus infrequent monitoring (frequency representative of routine clinical practice), specialised care versus usual care, and naïve versus prior anticoagulant use. Meta-analysis was performed using a random effects model.Results: 36 studies were included, 22 (primary data) of AF patients managed in line with the consensus guidelines target INR range of 2.0–3.0, and 14 studies (secondary data) of mixed patient groups, including AF...
- 22 November 2007
- Published by Wiley in Haemophilia
- Vol. 14 (1) , 78-80
Tyr346→Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype – is this mild haemophilia A?
Summary. Patients with mild haemophilia A may have a discrepancy in the factor VIII (FVIII) level when measured with a one‐stage assay (FVIII:C1) compared with a two‐stage assay (FVIII:C2). This discrepancy usually results in the one‐stage level being higher than the two‐stage level. A F8 mutation resulting in a Tyr346→Cys substitution within the a1 interdomain region has been described which results in the converse assay discrepancy. We report four individuals (three families) who have this mutation. Mean FVIII:C1 level was 25 IU dL−1 compared with a mean FVIII:C2 level of 63 IU dL−1. These individuals had presented opportunistically and did not have a clinically significant bleeding disorder. The bleeding phenotype correlated with the two‐stage assay result rather than the one‐stage result. FVIII replacement therapy does not appear to be required for these individuals.
- 22 November 2007
- Published by Wiley in Haemophilia
- Vol. 14 (1) , 78-80
Tyr346→Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype – is this mild haemophilia A?
Summary. Patients with mild haemophilia A may have a discrepancy in the factor VIII (FVIII) level when measured with a one‐stage assay (FVIII:C1) compared with a two‐stage assay (FVIII:C2). This discrepancy usually results in the one‐stage level being higher than the two‐stage level. A F8 mutation resulting in a Tyr346→Cys substitution within the a1 interdomain region has been described which results in the converse assay discrepancy. We report four individuals (three families) who have this mutation. Mean FVIII:C1 level was 25 IU dL−1 compared with a mean FVIII:C2 level of 63 IU dL−1. These individuals had presented opportunistically and did not have a clinically significant bleeding disorder. The bleeding phenotype correlated with the two‐stage assay result rather than the one‐stage result. FVIII replacement therapy does not appear to be required for these individuals.
- 27 January 2006
- Published by Wiley in Haemophilia
- Vol. 12 (s1) , 16-20
Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt–Jakob disease experience
Summary. The impact of variant Creutzfeldt–Jakob disease (vCJD) on the clinical practice of haemophilia in the UK is coloured by the haemophilia community's experience of hepatitis C virus and human immunodeficiency virus (HIV) transmission via plasma‐derived therapies in the 1980s, when the delay in recognizing and acting on the potential risks cost many patients their lives and left others to manage another chronic disease. This crisis prompted organisations such as the United Kingdom Haemophilia Centre Doctors’ Organisation to advocate for the introduction of haemophilia therapies that would not be susceptible to contamination with blood‐borne pathogens. After the identification of vCJD in 1996, a number of public health measures were taken in response to a government‐sponsored vCJD risk assessment, and following reports of transfusion‐transmission of vCJD, additional guidelines have been developed to prevent person‐to‐person transmission, some of which may impact the quality and availability of medical and surgical care. Variant CJD has had a significant negative effect on the UK haemophilia community, shaking patient confidence in the therapies they have received over the last 21 years, affecting the quality of care and creating the risk of stigmatizing the community as it was in the 1980s. As with HIV and vCJD, emerging blood‐borne infectious agents will likely affect blood and blood‐derived therapies well before we become aware of its presence. As a result, only therapies with the lowest level of risk should be used for care of patients with haemophilia.
- 27 January 2006
- Published by Wiley in Haemophilia
- Vol. 12 (s1) , 16-20
Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt–Jakob disease experience
Summary. The impact of variant Creutzfeldt–Jakob disease (vCJD) on the clinical practice of haemophilia in the UK is coloured by the haemophilia community's experience of hepatitis C virus and human immunodeficiency virus (HIV) transmission via plasma‐derived therapies in the 1980s, when the delay in recognizing and acting on the potential risks cost many patients their lives and left others to manage another chronic disease. This crisis prompted organisations such as the United Kingdom Haemophilia Centre Doctors’ Organisation to advocate for the introduction of haemophilia therapies that would not be susceptible to contamination with blood‐borne pathogens. After the identification of vCJD in 1996, a number of public health measures were taken in response to a government‐sponsored vCJD risk assessment, and following reports of transfusion‐transmission of vCJD, additional guidelines have been developed to prevent person‐to‐person transmission, some of which may impact the quality and availability of medical and surgical care. Variant CJD has had a significant negative effect on the UK haemophilia community, shaking patient confidence in the therapies they have received over the last 21 years, affecting the quality of care and creating the risk of stigmatizing the community as it was in the 1980s. As with HIV and vCJD, emerging blood‐borne infectious agents will likely affect blood and blood‐derived therapies well before we become aware of its presence. As a result, only therapies with the lowest level of risk should be used for care of patients with haemophilia.
- 7 October 2005
- Published by Wiley in Haemophilia
- Vol. 11 (s1) , 24-25
ESOS: a European study on the orthopaedic status of patients with haemophilia and inhibitors
Published studies highlight the paucity of data relating to orthopaedic health and quality of life in haemophilia patients with inhibitors. A European Study on the Orthopaedic Status of Patients with Haemophilia and Inhibitors (ESOS) has been set up to address this lack of data. This cross-sectional retrospective study aims to enrol 400 patients from 50 sites in nine European countries. The primary outcome measure of the study is the burden of orthopaedic complications in patients with severe haemophilia and inhibitors. The data that will be generated should demonstrate the high level of arthropathy in haemophilia patients with inhibitors and show the need to focus on improving orthopaedic health in this rare, but particularly vulnerable, patient population.
- 7 October 2005
- Published by Wiley in Haemophilia
- Vol. 11 (s1) , 24-25
ESOS: a European study on the orthopaedic status of patients with haemophilia and inhibitors
Published studies highlight the paucity of data relating to orthopaedic health and quality of life in haemophilia patients with inhibitors. A European Study on the Orthopaedic Status of Patients with Haemophilia and Inhibitors (ESOS) has been set up to address this lack of data. This cross-sectional retrospective study aims to enrol 400 patients from 50 sites in nine European countries. The primary outcome measure of the study is the burden of orthopaedic complications in patients with severe haemophilia and inhibitors. The data that will be generated should demonstrate the high level of arthropathy in haemophilia patients with inhibitors and show the need to focus on improving orthopaedic health in this rare, but particularly vulnerable, patient population.